

subsequently administering at least one cytokine to said patient;  
wherein said transfected T cells are produced by obtaining T cells from the patient and transfecting said T cells with an expression vector to obtain said transfected T cells;  
wherein said expression vector comprises a DNA molecule encoding either a chimeric immunoglobulin/T cell receptor or a chimeric immunoglobulin/CD3 protein, and wherein said immunoglobulin-encoding portion of said DNA molecule encodes the variable region of a Class III anti-CEA antibody, and further wherein the variable regions of the  $\alpha$  and  $\beta$  polypeptide chains of said T cell receptor are replaced by said variable regions of the antibody.

52. (Amended) A method for inducing a cellular immune response in a patient against a tumor that expresses carcinoembryonic antigen (CEA), said method comprising:  
administering an effective immunostimulatory amount of transfected T cells to a patient; and

subsequently administering at least one cytokine to said patient;  
wherein said T cells are produced by obtaining T cells from the patient and transfecting said T cells with an expression vector to obtain said transfected T cells;  
wherein said expression vector comprises a DNA molecule encoding either a chimeric immunoglobulin/T cell receptor or a chimeric immunoglobulin/CD3 protein, and wherein said immunoglobulin-encoding portion of said DNA molecule encodes the variable region of an anti-idiotypic antibody that recognizes a Class III anti-CEA antibody, and further wherein the variable regions of the  $\alpha$  and  $\beta$  polypeptide chains of said T cell receptor are replaced by said variable regions of the antibody.

Kindly add the following claims:

58. (New) The method of claim 48, wherein the Class III anti-CEA antibody is MN-14 or humanized MN-14.

59. (New) The method of claim 52, wherein the anti-idiotypic antibody is WI2.